| 产品名称： | AML-193 |
|---|---|
| 商品货号： | TS212668 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | monocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute monocytic leukemia |
| Age： | 13 years |
| Gender： | female |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype： | This is a hyperdiploid human cell line. The modal chromosome number is 49, occurring in 50% of cells. The rate of polyploidy is 2.2%. There is one marker chromosome, der(17)t(17;17)(p13.1;q21.3), that occurred in every cell. These cells are trisomic for N3, N6, N8, and N13, and occasionally also for N2. N17 and X chromosome had a single copy, but occasionally the X had two copies. Thus the modal karyotype of this cell line is 49, X, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17. The subline with 50, X, +2, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17 and 50, XX, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3, -17 also occurred, but at a very low frequency. |
| Derivation： | This line was formerly designated ATCC HTB-188. |
| Clinical Data： | female |
| Antigen Expression： | CD15, human; Homo sapiens, expressed (75 to 95% of the cells) (75 to 95% of the cells) |
| Genes Expressed： | CD15, human; Homo sapiens, expressed (75 to 95% of the cells) |
| Comments： | Interleukin-3 (interleukin 3, IL-3) and granulocyte/macrophage colony stimulating factor (GM-CSF) act synergistically to stimulate growth of the cells. Granulocyte colony stimulating factor (G-CSF) also supports short term and long term growth of AML-193 cells and acts synergistically with GM-CSF in inducing proliferation of the cells.
|
| Complete Growth Medium： | Iscoves modified Dulbeccos medium with 0.005 mg/ml insulin, 0.005 mg/ml transferrin and 5 ng/ml GM-CSF, 95%; fetal bovine serum, 5%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 105 cells/mL and maintain between 3 X 105 and 1 X 106 cells/mL.
Medium Renewal: Every 2 to 3 days Note: The cells are dependent upon GM-CSF for long term growth. Conditioned medium from U-87MG (ATCC HTB-14) may be used at a concentration of 10% to replace the GM-CSF in the medium (see J. Immunol. 139:3348- 3354, 1987).
|
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 11,12 D13S317: 12 D16S539: 12 D5S818: 9,13 D7S820: 9,12 THO1: 7,9 TPOX: 8,9 vWA: 15,17 |
| Name of Depositor： | Wistar Institute |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| References： | Lange B, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70: 192-199, 1987. PubMed: 3496132 Santoli D, et al. Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 alpha, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139: 3348-3354, 1987. PubMed: 3500218 75 to 95% of the cells |
产品中心 Product Center
联系我们CONTACT US
-
0574-87917803
24小时服务热线 -
testobio@163.com
销售邮箱 -
浙江省宁波市高新区晶辉路866弄33号智造港E4幢3楼
地址
联系方式
-
章丽敏
17757489010 -
朱静
18067106081 -
李晴
18067408036 -
李晶晶
13375187189 -
周雪
13372109301
| 产品名称： | AML-193 |
|---|---|
| 商品货号： | TS212668 |
| Organism： | Homo sapiens, human |
| Tissue： | peripheral blood |
| Cell Type： | monocyte |
| Product Format： | frozen |
| Morphology： | lymphoblast |
| Culture Properties： | suspension |
| Biosafety Level： | 1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease： | acute monocytic leukemia |
| Age： | 13 years |
| Gender： | female |
| Storage Conditions： | liquid nitrogen vapor phase |
| Disclosure： | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Karyotype： | This is a hyperdiploid human cell line. The modal chromosome number is 49, occurring in 50% of cells. The rate of polyploidy is 2.2%. There is one marker chromosome, der(17)t(17;17)(p13.1;q21.3), that occurred in every cell. These cells are trisomic for N3, N6, N8, and N13, and occasionally also for N2. N17 and X chromosome had a single copy, but occasionally the X had two copies. Thus the modal karyotype of this cell line is 49, X, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17. The subline with 50, X, +2, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3), -17 and 50, XX, +3, +6, +8, +der(17)t(17;17)(p13.1;q21.3, -17 also occurred, but at a very low frequency. |
| Derivation： | This line was formerly designated ATCC HTB-188. |
| Clinical Data： | female |
| Antigen Expression： | CD15, human; Homo sapiens, expressed (75 to 95% of the cells) (75 to 95% of the cells) |
| Genes Expressed： | CD15, human; Homo sapiens, expressed (75 to 95% of the cells) |
| Comments： | Interleukin-3 (interleukin 3, IL-3) and granulocyte/macrophage colony stimulating factor (GM-CSF) act synergistically to stimulate growth of the cells. Granulocyte colony stimulating factor (G-CSF) also supports short term and long term growth of AML-193 cells and acts synergistically with GM-CSF in inducing proliferation of the cells.
|
| Complete Growth Medium： | Iscoves modified Dulbeccos medium with 0.005 mg/ml insulin, 0.005 mg/ml transferrin and 5 ng/ml GM-CSF, 95%; fetal bovine serum, 5%.
|
| Subculturing： | Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 X 105 cells/mL and maintain between 3 X 105 and 1 X 106 cells/mL.
Medium Renewal: Every 2 to 3 days Note: The cells are dependent upon GM-CSF for long term growth. Conditioned medium from U-87MG (ATCC HTB-14) may be used at a concentration of 10% to replace the GM-CSF in the medium (see J. Immunol. 139:3348- 3354, 1987).
|
| Cryopreservation： | Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions： | Temperature: 37°C |
| STR Profile： | Amelogenin: X CSF1PO: 11,12 D13S317: 12 D16S539: 12 D5S818: 9,13 D7S820: 9,12 THO1: 7,9 TPOX: 8,9 vWA: 15,17 |
| Name of Depositor： | Wistar Institute |
| Deposited As： | Homo sapiens |
| U.S. Patent Number： | |
| References： | Lange B, et al. Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70: 192-199, 1987. PubMed: 3496132 Santoli D, et al. Synergistic and antagonistic effects of recombinant human interleukin (IL) 3, IL-1 alpha, granulocyte and macrophage colony-stimulating factors (G-CSF and M-CSF) on the growth of GM-CSF-dependent leukemic cell lines. J. Immunol. 139: 3348-3354, 1987. PubMed: 3500218 75 to 95% of the cells |
